Tags

Type your tag names separated by a space and hit enter

Severe paradoxical disease activation following alemtuzumab treatment for multiple sclerosis.

Authors+Show Affiliations

From Jesus College (J.B., S.R.L.S.), Cambridge University, UK; Department of Neurology (J.L.J., S.R.L.S.), Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; and Department of Neurology (S.R.L.S.), Peterborough City Hospital, North West Anglia NHS Foundation Trust, Peterborough, UK.From Jesus College (J.B., S.R.L.S.), Cambridge University, UK; Department of Neurology (J.L.J., S.R.L.S.), Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; and Department of Neurology (S.R.L.S.), Peterborough City Hospital, North West Anglia NHS Foundation Trust, Peterborough, UK.From Jesus College (J.B., S.R.L.S.), Cambridge University, UK; Department of Neurology (J.L.J., S.R.L.S.), Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; and Department of Neurology (S.R.L.S.), Peterborough City Hospital, North West Anglia NHS Foundation Trust, Peterborough, UK. srls2@cam.ac.uk.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32522766

Citation

Brannigan, Jamie, et al. "Severe Paradoxical Disease Activation Following Alemtuzumab Treatment for Multiple Sclerosis." Neurology(R) Neuroimmunology & Neuroinflammation, vol. 7, no. 5, 2020.
Brannigan J, Jones JL, Stacpoole SRL. Severe paradoxical disease activation following alemtuzumab treatment for multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2020;7(5).
Brannigan, J., Jones, J. L., & Stacpoole, S. R. L. (2020). Severe paradoxical disease activation following alemtuzumab treatment for multiple sclerosis. Neurology(R) Neuroimmunology & Neuroinflammation, 7(5). https://doi.org/10.1212/NXI.0000000000000799
Brannigan J, Jones JL, Stacpoole SRL. Severe Paradoxical Disease Activation Following Alemtuzumab Treatment for Multiple Sclerosis. Neurol Neuroimmunol Neuroinflamm. 2020;7(5) PubMed PMID: 32522766.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Severe paradoxical disease activation following alemtuzumab treatment for multiple sclerosis. AU - Brannigan,Jamie, AU - Jones,Joanne L, AU - Stacpoole,Sybil R L, Y1 - 2020/06/10/ PY - 2020/01/06/received PY - 2020/04/22/accepted PY - 2020/6/12/entrez PY - 2020/6/12/pubmed PY - 2020/6/12/medline JF - Neurology(R) neuroimmunology & neuroinflammation JO - Neurol Neuroimmunol Neuroinflamm VL - 7 IS - 5 SN - 2332-7812 UR - https://www.unboundmedicine.com/medline/citation/32522766/Severe_paradoxical_disease_activation_following_alemtuzumab_treatment_for_multiple_sclerosis L2 - http://nn.neurology.org/cgi/pmidlookup?view=long&pmid=32522766 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.